NCT06174753View on ClinicalTrials.gov

Dapagliflozin in STEMI

PHASE3RecruitingINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

September 30, 2026

Conditions
ST Elevation Myocardial InfarctionMyocardial Infarction
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10 mg daily X 7 days

DIAGNOSTIC_TEST

CMR

CMR 3-5 days post randomization

Trial Locations (1)

K1Y 4W7

RECRUITING

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER